AVBP
HEALTHCAREArriVent BioPharma Inc
Live · NASDAQ · May 9, Close
What's Moving AVBP Today?
No stock-specific AI insight has been generated for AVBP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$29.62
Fundamentals
Trading
AVBP News
20 articles- ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial CancersYahoo Finance·May 7, 2026
- Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great ChoiceYahoo Finance·Apr 15, 2026
- Are Medical Stocks Lagging AstraZeneca (AZN) This Year?Yahoo Finance·Apr 13, 2026
- Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a BetYahoo Finance·Apr 6, 2026
- Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline InterestYahoo Finance·Apr 5, 2026
- Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?Yahoo Finance·Mar 26, 2026
- ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual MeetingYahoo Finance·Mar 17, 2026
- Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026Yahoo Finance·Mar 17, 2026
- Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?Yahoo Finance·Mar 10, 2026
- Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Mar 10, 2026
- ArriVent BioPharma Reports Full Year 2025 Financial ResultsYahoo Finance·Mar 5, 2026
- EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightYahoo Finance·Feb 11, 2026
- Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More247 Wall St·Dec 23, 2025
- ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung CancerYahoo Finance·Dec 22, 2025
- We Think ArriVent BioPharma (NASDAQ:AVBP) Needs To Drive Business Growth CarefullyYahoo Finance·Nov 12, 2025
- ArriVent BioPharma Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 10, 2025
- ArriVent Appoints Brent S. Rice as Chief Commercial OfficerYahoo Finance·Sep 22, 2025
- Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung CancerYahoo Finance·Sep 9, 2025
- ArriVent BioPharma Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 11, 2025
- ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026Yahoo Finance·Jul 21, 2025
All 20 articles loaded
Price Data
52-Week Range
$29.62
Fundamentals
Trading
About ArriVent BioPharma Inc
ArriVent BioPharma, Inc. (AVBP) is a biopharmaceutical innovator focused on delivering groundbreaking therapies to address critical unmet medical needs in oncology and autoimmune disorders. The company boasts a robust pipeline of therapies, employing proprietary technologies backed by a strong scientific framework, which are designed to enhance patient outcomes considerably. By concentrating on high-growth sectors within the biopharma landscape, ArriVent positions itself as an attractive investment opportunity for institutional investors looking to engage in transformative healthcare solutions that hold the promise of significant market impact.